Multiple Myeloma | Topics

 
Longer Follow-Up Shows Cilta-Cel Induces Deep, Durable Responses in Relapsed/Refractory MM
June 19, 2021

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, Talks About Durable and Deep Responses of Cilta-Cel for Patients With Multiple Myeloma
June 16, 2021

Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.

Daratumumab Plus CyBorD Followed by Daratumumab Maintenance Achieves Deep Responses for Multiple Myeloma
June 16, 2021

An end-of-study analysis of the LYRA trial found that patients with treatment-naïve and relapsed multiple myeloma achieved durable responses to daratumumab plus CyBorD induction followed by daratumumab maintenance therapy.